ArticleHepatology (Baltimore, Md.)2014

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

Koen Vercauteren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.